Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes program helps latinx patients better manage blood sugar

NCT ID NCT05394844

Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a culturally tailored diabetes education program, called Compañeros en Salud, combined with a continuous glucose monitor (CGM) helps Latinx adults with type 2 diabetes control their blood sugar better than education alone. 120 adults aged 18-60 with an A1C of 8% or higher took part. The goal was to see if adding real-time glucose tracking to the education program improves A1C levels and other health measures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Nov 2022

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participants adults 18-60 years old 2. Self-identify as Latinx 3. Have had a clinical diagnosis of T2D within the last 15 years with or without medication use 4. Have an A1C ≥8.0% at screening 5. Own or have routine access to a personal device that allows attending educational sessions virtually 6. Be physically and cognitively able to use the home CGM monitoring device 7. Be willing and able to follow all other study procedures Exclusion Criteria * Exclusion Criteria. 1. Duration of diabetes \>15 years 2. Type 1 diabetes or latent autoimmune diabetes 3. Current use of prandial insulin 4. Any condition that prevents walking at least 1 city block 5. History of serious mental illness other than adequately treated depression 6. History of bariatric surgery or current participation in a weight management program 7. Current diagnosis of cancer or other serious or systemic medical condition 8. Significant active cardio- or cerebrovascular disease after review by PI 9. Pregnancy 10. know history x of of hypoglycemia unawareness 11. Unable to read, understand, and sign the Informed Consent Form (ICF) and if applicable, an Authorization to Use and Disclose Protected Health Information form (consistent with Health Insurance Portability and Accountability Act of 1996 \[HIPAA\] legislation), communicate with the investigator, and understand and comply with protocol requirements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes type 2

Contacts and locations

Locations

  • University of Washington

    Seattle, Washington, 98109, United States

  • University of Washington Diabetes Institute

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.